ALCJ Crossject Société Anonyme
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Crossject (EPA: ALCJ)
›
Crossject (EPA: ALCJ) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 110 employees.
The shares were at 1.338 EUR on 19 November 2026, down 43.3% over 52 weeks. Its 52-week range is 1.100 EUR to 2.580 EUR: the price is 48.1% below the high and 21.6% above the low.
Its market capitalisation is 81.24M EUR.
Crossject reports return on equity of 212.7%.
Its debt exceeds its cash by 7.80M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 4.150 EUR is 210.2% above the current price.